View Item 

Show simple item record

Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion
dc.contributor.authorMcSwain, C. Shaneen_US
dc.contributor.authorBenza, Rayen_US
dc.contributor.authorShapiro, Shelleyen_US
dc.contributor.authorHill, Nicholasen_US
dc.contributor.authorSchilz, Roberten_US
dc.contributor.authorElliott, C. Gregoryen_US
dc.contributor.authorZwicke, Diann L.en_US
dc.contributor.authorOudiz, Ronal J.en_US
dc.contributor.authorStaszewski, Jame P.en_US
dc.contributor.authorArneson, Car P.en_US
dc.contributor.authorWade, Michaelen_US
dc.contributor.authorZaccardelli, Daviden_US
dc.contributor.authorMcLaughlin, Vallerieen_US
dc.date.accessioned2013-04-08T20:50:12Z
dc.date.available2013-04-08T20:50:12Z
dc.date.issued2008-01en_US
dc.identifier.citationMcSwain, C. Shane; Benza, Ray; Shapiro, Shelley; Hill, Nicholas; Schilz, Robert; Elliott, C. Gregory; Zwicke, Diann L.; Oudiz, Ronal J.; Staszewski, Jame P.; Arneson, Car P.; Wade, Michael; Zaccardelli, David; McLaughlin, Vallerie (2008). "Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion." The Journal of Clinical Pharmacology 48(1). <http://hdl.handle.net/2027.42/97290>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97290
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPulmonary Arterial Hypertension (PAH)en_US
dc.subject.otherProstacyclinen_US
dc.subject.otherPharmacokineticen_US
dc.subject.otherTreprostinilen_US
dc.titleDose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherUnited Therapeutics Corporation, Research Triangle Park, North Carolinaen_US
dc.contributor.affiliationotherUniversity of Alabama, Birminghamen_US
dc.contributor.affiliationotherWest Los Angeles VA Healthcare Center, Los Angeles, Californiaen_US
dc.contributor.affiliationotherTufts‐New England Medical Center, Boston, Massachusettsen_US
dc.contributor.affiliationotherUniversity Hospitals of Cleveland, Cleveland, Ohioen_US
dc.contributor.affiliationotherLDS Hospital and University of Utah, Salt Lake Cityen_US
dc.contributor.affiliationotherSt. Luke's Medical Center, Milwaukee, Wisconsinen_US
dc.contributor.affiliationotherLA Biomedical Research Institute at Harbor‐UCLA Medical Center, Torrance, Californiaen_US
dc.identifier.pmid18094217en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97290/1/0091270007309708.pdf
dc.identifier.doi10.1177/0091270007309708en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceBarst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334: 296 – 302.en_US
dc.identifier.citedreferenceChristman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327: 70 – 75.en_US
dc.identifier.citedreferenceVane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995; 75: 3A – 10A.en_US
dc.identifier.citedreferenceSkoro‐Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2007; 5: 483 – 489.en_US
dc.identifier.citedreferenceWade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004; 44: 83 – 88.en_US
dc.identifier.citedreferenceWade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28‐day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004; 44: 503 – 509.en_US
dc.identifier.citedreferenceRemodulin r̀ (treprostinil sodium) [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2002.en_US
dc.identifier.citedreferenceLaliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady‐state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004; 44: 209 – 214.en_US
dc.identifier.citedreferenceTapson VF, Gomberg‐Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open‐label, 12‐week trial. Chest. 2006; 129: 683 – 688.en_US
dc.identifier.citedreferenceMcLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003; 41: 293 – 299.en_US
dc.identifier.citedreferenceSimonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double‐blind, randomized, placebo‐controlled trial. Am J Respir Crit Care Med. 2002; 165: 800 – 804.en_US
dc.identifier.citedreferenceBadesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000; 132: 425 – 434.en_US
dc.identifier.citedreferenceSitbon O, Manes A, Jais X, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2007; 49: 1 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270007309708.pdf
Size:
425.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.